NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Remains Focused on Further Development of Vadadustat
Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company engaged in discovering and developing novel therapeutic solutions that leverage hypoxia inducible factor (HIF) biology, a primary regulator involved in multiple major biological pathways. According to an earlier Aegis report (http://nnw.fm/F4ezY), Akebia’s lead product candidate, vadadustat, has an impressive 60 percent probability of clinical success. Vadadustat is currently in phase III trials, after encouraging results were reported during phase II testing. In December 2016, Akebia signed a collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of…







